The agreement specifies exclusivity for the products for the institutional / healthcare market and includes an adult incontinence cream, skin barrier cream and super moisturizer.
The agreement specifies upfront license fees for the territories of Europe and China and milestone payments based on approvals and launch dates for the US.
In addition, Skinvisible is expected to get royalties on sales of the products. However, RHEI will take up the responsibility for regulatory filings, manufacturing and commercialization of the products.
RHEI will leverage its affiliate BeoCare Group to provide access to the institutional / healthcare markets through its established network of multi-national clients.
Peter Vanderbruggen, managing director of leeward ventures SICAR SCA and president of BeoCare Group, said: “Skinvisible brings us products that can be leveraged by the three healthcare-related companies in our portfolio.
“We are pleased to collaborate with Skinvisible on the commercialisation of these products, which represents a significant expansion of our current medical product lines.”